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The prevalence of asthma, particularly in children, 
has increased globally in recent decades. As a pedi-
atrician, I was pleased to see that guidelines for 
the treatment of childhood asthma were recently 
published by the Global Initiative for Asthma.1 
These guidelines provide a good consensus for the 
diagnosis and treatment of childhood asthma, even 
in children younger than 5 years old. Asthma-
controlling medication that tastes good and is ad-
ministered by user-friendly devices has been shown 
to prevent asthma symptoms and improve lung 
function.
Most children with asthma have mild-to-moderate 
asthma, which usually responds to low-dose in-
haled corticosteroids (ICS) or to nonsteroidal anti-
inflammatory drugs, such as leukotriene antaonists, 
theophylline and ketotifen. For children with mod-
erate-to-severe asthma, double doses of ICS or 
oral corticosteroids can usually control the asthma 
symptoms and effectively prevent attacks. Alter-
natively, add-on subcutaneous immunotherapy with 
extracts of specific allergens has been shown to 
be effective for hay fever and asthma. In Taiwan, 
the most common allergens are Dermatophagoides 
pteronyssinus (Der P) and Dermatophagoides fari-
nae (Der F). Previous studies have demonstrated 
that subcutaneous or sublingual immunotherapy 
with house dust mites or their antigens, Der P and 
Der F, had beneficial effects in children with asthma, 
in terms of decreased symptom scores and medi-
cation requirements. A study by Tsai et al2 reported 
in this issue, reproduced the beneficial effects of 
subcutaneous immunotherapy with Der P and Der F 
allergens on the control of childhood asthma. Re-
cent studies have introduced the use of a combi-
nation of specific allergen immunotherapy with 
anti-IgE (omalizumab) treatment in patients with 
moderate-to-severe asthma; it was demonstrated 
that pretreatment with the monoclonal anti-IgE 
antibody for 9 weeks reduced systemic reactions 
during rush immunother apy five-fold.3 Moreover, 
clinical trials with Toll-like receptor 9 vaccines 
conjugated to a ragweed allergen or with anti-
interleukin-5 therapy have been shown to be ef-
fective as corticosteroid-sparing agents in patients 
with allergic disorders.4 However, asthma is usu-
ally not curable, even with ICS, immunotherapy, 
and/or anti-IgE (omalizumab) therapy.
Asthma is a complex disease whose reversibility 
and progression is affected by chronic inflamma-
tion, hyperresponsiveness, and neuromuscular re-
modeling. It is therefore necessary to identify the 
roles of these complex compartments in the re-
versal or progression of asthma. To this end, an-
other study in this issue by Kuo et al5 demonstrated 
that the administration of different brands of ICS 
to asthmatic children reduced asthma symptoms, 
but induced varying effects on the production of 
cytokines and exhaled nitric oxide levels. Asthma 
appears to be a complex disease that can remit 
or progress and can respond to environmental 
factors, including medication.
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Asthma has long been recognized as a hereditary 
disorder. However, the prevalence of childhood 
asthma in different countries ranges from less than 
1% in Tibet (China) to greater than 30% in New 
Zealand. Various genome-wide studies have identi-
fied more than 100 genes on 22 chromosomes that 
are associated with asthma.6−8 A number of studies 
also found different genetic backgrounds in differ-
ent environments could modulate susceptibility to 
different allergic disorders.9,10 This suggests that 
allergic diseases, although heritable, are signifi-
cantly affected by environmental factors that can 
modulate the progression or remission of asthma 
via epigenetic programming.
The influence of the perinatal environment on 
the epigenetic programming of adult diseases has 
been linked to diabetes, cardiovascular diseases and 
kidney diseases. It has also been postulated that 
certain genes can be epigenetically modified by 
environmental factors during the perinatal stage, 
thus priming individuals to develop childhood asthma 
and rhinitis. To this end, we have been studying a 
birth cohort from the antenatal stage to 6 years 
old to clarify the effects of the gene-environment 
interaction on the development of asthma. Progress 
reports of this cohort study have shown that certain 
genes can interact with maternal atopy to affect 
prenatal IgE production and atopic dermatitis.11−13 
However, a different gene which is not correlated 
to allergy sensitization, is involved in the develop-
ment of infant wheezing.14 Further studies have 
investigated the occurrence of epigenetic program-
ming of asthma and rhinitis during the perinatal 
stage in this cohort. Clarification of the perinatal 
epigenetic programming of childhood asthma and 
rhinitis may highlight prospects for the early pre-
diction and prevention of childhood asthma and 
rhinitis by epigenetic modulation.
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